Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

By P. Heinrich, I. Behrmann, S. Haan, H. Hermanns, G. Müller-Newen, F. Schaper. Biochemical Journal, 2003

3,403 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/492e4537daa1c598ed563f2647db929ad1dba97f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. T. Hirano
2. T. Tchkonia
3. Shinwan Kany
4. A. Stolzing
5. J. Kirkland
6. A. Scutt
7. B. Relja
8. Jan T Vollrath

In Oncology

1. S. Rose‐John
2. T. Hirano
3. Simon A. Jones
4. J. Scheller
5. Christopher A. Hunter
6. P. Lupardus
7. J. Hidalgo
8. Albert Quintana

In Pharmacology

1. R. Taub

Citations in the corpus

• Interleukin-6, a Major Cytokine in the Central Nervous System (2012, background): “IL-6 is a prototypical four-helix bundle cytokine that is the founder member of the neuropoietins, a group of cytokines structurally related, that include IL-6, IL-11, IL-27, IL-31, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, neuropoietin and cytokine cardiotrophin-like (also known as”
• IL-6 in inflammation, autoimmunity and cancer (2020, background): “Activated JAK phos-phorylates tyrosine residues in the cytoplasmic domain of gp130 (30, 31, 61, 62, 102, 103).”
• Aging of mesenchymal stem cells. (2006, background): “Interleukin-6 (IL-6) Interleukin-6 (IL-6) is a cytokine capable of regulating proliferation, differentiation and activity of a variety of cell types (Heinrich et al., 2003).”
• The JAK/STAT signaling pathway (2004, neutral): “Mechanistically, JAK/STAT signaling is relatively simple, with only a few principal components (for reviews, see Aaronson and Horvath, 2002; Heinrich et al., 2003; Kisseleva et al., 2002; O’Shea et al., 2002).”
• Inflammatory Cytokines in Experimental and Human Stroke (2012, background): “…allows the formation of gp130/gp130 homodimers that associates with Janusassociated kinases, activates signal transducer and activator of transcription and mitogen-activated protein kinase signaling pathways (Heinrich et al, 2003; Kamimura et al, 2003; Ernst and Jenkins, 2004; Bauer et al, 2007).”
• Obesity and Cancer: The Role of Dysfunctional Adipose Tissue (2009, background): “Effects of IL-6 on cell proliferation and cell survival are likely to be mediated through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)3 pathway (127).”
• Intracellular signalling pathways activated by leptin. (2006, background): “…receptors, such as the gp130 (glycoprotein 130) subunit of the IL-6 receptor family, suggested the possibility that leptin binding might mediate cytokine receptor-like signals, including the activation of JAKs (Janus kinases) and STATs (signal transducers and activators of transcription) [76–78].”
• Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 (2005, background): “signaling, the reader is referred elsewhere (24).”